Please use a PC Browser to access Register-Tadawul
Get It
A Glimpse Into The Expert Outlook On ACADIA Pharmaceuticals Through 11 Analysts
ACADIA Pharmaceuticals Inc. -1.40%
ACADIA Pharmaceuticals Inc. ACAD | 23.99 | -1.40% |
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on ACADIA Pharmaceuticals (NASDAQ:ACAD) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 4 | 2 | 0 | 0 |
| Last 30D | 1 | 2 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $32.82, with a high estimate of $40.00 and a low estimate of $25.00. Surpassing the previous average price target of $31.73, the current average has increased by 3.44%.
Decoding Analyst Ratings: A Detailed Look
The standing of ACADIA Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Lowers | Outperform | $31.00 | $35.00 |
| Jason N. Butler | Citizens | Maintains | Market Outperform | $34.00 | $34.00 |
| Ananda Ghosh | HC Wainwright & Co. | Maintains | Buy | $37.00 | $37.00 |
| Yigal Nochomovitz | Citigroup | Raises | Buy | $36.00 | $33.00 |
| Ashwani Verma | UBS | Raises | Buy | $40.00 | $35.00 |
| Ananda Ghosh | HC Wainwright & Co. | Raises | Buy | $37.00 | $32.00 |
| Paul Matteis | Stifel | Raises | Hold | $25.00 | $24.00 |
| Uy Ear | Mizuho | Raises | Neutral | $29.00 | $24.00 |
| Tessa Romero | JP Morgan | Lowers | Overweight | $31.00 | $33.00 |
| Brian Abrahams | RBC Capital | Lowers | Outperform | $32.00 | $34.00 |
| Ami Fadia | Needham | Raises | Buy | $29.00 | $28.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ACADIA Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ACADIA Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into ACADIA Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on ACADIA Pharmaceuticals analyst ratings.
All You Need to Know About ACADIA Pharmaceuticals
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Financial Insights: ACADIA Pharmaceuticals
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 11.27% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ACADIA Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 25.76%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 8.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ACADIA Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
